These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 37934007)

  • 1. Disruption of SUV39H1-Mediated H3K9 Methylation Sustains CAR T-cell Function.
    Jain N; Zhao Z; Koche RP; Antelope C; Gozlan Y; Montalbano A; Brocks D; Lopez M; Dobrin A; Shi Y; Gunset G; Giavridis T; Sadelain M
    Cancer Discov; 2024 Jan; 14(1):142-157. PubMed ID: 37934007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SUV39H1 Ablation Enhances Long-term CAR T Function in Solid Tumors.
    López-Cobo S; Fuentealba JR; Gueguen P; Bonté PE; Tsalkitzi K; Chacón I; Glauzy S; Bohineust A; Biquand A; Silva L; Gouveia Z; Goudot C; Perez F; Saitakis M; Amigorena S
    Cancer Discov; 2024 Jan; 14(1):120-141. PubMed ID: 37934001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic reprogramming of CAR T cells for in vivo functional persistence against solid tumors.
    Saitakis M
    Genes Immun; 2024 Oct; 25(5):434-436. PubMed ID: 38388813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulated Expansion and Survival of Chimeric Antigen Receptor-Modified T Cells Using Small Molecule-Dependent Inducible MyD88/CD40.
    Foster AE; Mahendravada A; Shinners NP; Chang WC; Crisostomo J; Lu A; Khalil M; Morschl E; Shaw JL; Saha S; Duong MT; Collinson-Pautz MR; Torres DL; Rodriguez T; Pentcheva-Hoang T; Bayle JH; Slawin KM; Spencer DM
    Mol Ther; 2017 Sep; 25(9):2176-2188. PubMed ID: 28697888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vivo Expansion and Antitumor Activity of Coinfused CD28- and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia.
    Cheng Z; Wei R; Ma Q; Shi L; He F; Shi Z; Jin T; Xie R; Wei B; Chen J; Fang H; Han X; Rohrs JA; Bryson P; Liu Y; Li QJ; Zhu B; Wang P
    Mol Ther; 2018 Apr; 26(4):976-985. PubMed ID: 29503204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inclusion of 4-1BB Costimulation Enhances Selectivity and Functionality of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells.
    Starr R; Aguilar B; Gumber D; Maker M; Huard S; Wang D; Chang WC; Brito A; Chiu V; Ostberg JR; Badie B; Forman SJ; Alizadeh D; Wang LD; Brown CE
    Cancer Res Commun; 2023 Jan; 3(1):66-79. PubMed ID: 36968221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2
    Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE
    Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641
    [No Abstract]   [Full Text] [Related]  

  • 8. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
    Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
    Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
    Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
    Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Herpes Virus Entry Mediator Costimulation Signaling Enhances CAR T-cell Efficacy Against Solid Tumors Through Metabolic Reprogramming.
    Sun S; Huang C; Lu M; Xu H; Yuan Y; Zhao W; Hu X; Wang B; Zhang W; Gao X; Zheng J; Su L; Zhang Q
    Cancer Immunol Res; 2023 Apr; 11(4):515-529. PubMed ID: 36689620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD28 Costimulatory Domain-Targeted Mutations Enhance Chimeric Antigen Receptor T-cell Function.
    Boucher JC; Li G; Kotani H; Cabral ML; Morrissey D; Lee SB; Spitler K; Beatty NJ; Cervantes EV; Shrestha B; Yu B; Kazi A; Wang X; Sebti SM; Davila ML
    Cancer Immunol Res; 2021 Jan; 9(1):62-74. PubMed ID: 33188139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Replacing CAR-T cell resistance with persistence by changing a single residue.
    Hsieh EM; Scherer LD; Rouce RH
    J Clin Invest; 2020 Jun; 130(6):2806-2808. PubMed ID: 32364534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells.
    Roselli E; Boucher JC; Li G; Kotani H; Spitler K; Reid K; Cervantes EV; Bulliard Y; Tu N; Lee SB; Yu B; Locke FL; Davila ML
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34706886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.
    Pituch KC; Miska J; Krenciute G; Panek WK; Li G; Rodriguez-Cruz T; Wu M; Han Y; Lesniak MS; Gottschalk S; Balyasnikova IV
    Mol Ther; 2018 Apr; 26(4):986-995. PubMed ID: 29503195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells.
    Zolov SN; Rietberg SP; Bonifant CL
    Cytotherapy; 2018 Oct; 20(10):1259-1266. PubMed ID: 30309710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity.
    Prinzing B; Zebley CC; Petersen CT; Fan Y; Anido AA; Yi Z; Nguyen P; Houke H; Bell M; Haydar D; Brown C; Boi SK; Alli S; Crawford JC; Riberdy JM; Park JJ; Zhou S; Velasquez MP; DeRenzo C; Lazzarotto CR; Tsai SQ; Vogel P; Pruett-Miller SM; Langfitt DM; Gottschalk S; Youngblood B; Krenciute G
    Sci Transl Med; 2021 Nov; 13(620):eabh0272. PubMed ID: 34788079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct functions of CAR-T cells possessing a dectin-1 intracellular signaling domain.
    Liang X; Huang Y; Li D; Yang X; Jiang L; Zhou W; Su J; Chen N; Wang W
    Gene Ther; 2023 May; 30(5):411-420. PubMed ID: 33953316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy.
    Urak R; Walter M; Lim L; Wong CW; Budde LE; Thomas S; Forman SJ; Wang X
    J Immunother Cancer; 2017; 5():26. PubMed ID: 28331616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single residue in CD28-costimulated CAR-T cells limits long-term persistence and antitumor durability.
    Guedan S; Madar A; Casado-Medrano V; Shaw C; Wing A; Liu F; Young RM; June CH; Posey AD
    J Clin Invest; 2020 Jun; 130(6):3087-3097. PubMed ID: 32069268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual Targeting CAR-T Cells with Optimal Costimulation and Metabolic Fitness enhance Antitumor Activity and Prevent Escape in Solid Tumors.
    Hirabayashi K; Du H; Xu Y; Shou P; Zhou X; Fucá G; Landoni E; Sun C; Chen Y; Savoldo B; Dotti G
    Nat Cancer; 2021 Sep; 2(9):904-918. PubMed ID: 34746799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.